Revolve Biotechnologies Awarded $450K Phase I SBIR to develop IR fluorescent proteins for deep brain imaging

Baltimore, MD (August 24, 2015) – Revolve Biotechnologies, Inc. has been awarded a $450K Phase I Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH) – National Institute of Mental Health (NIMH) to develop iRFP-Max, a near-infrared fluorescent protein research tool that will enable *in vivo* imaging of brain and other tissues up to ten-fold deeper than currently available tools. Current fluorescent protein tools operate at wavelengths at which tissue absorbance allows scientists to image only close to the surface. This tool will enable a range of new applications and has the potential to become the industry standard for pre-clinical *in vivo* imaging for drug development and neuroscience research for diseases such as Alzheimer's and Parkinson's.

Revolve Biotechnologies is a life science company focused on engineering better proteins using novel directed evolution technologies. The company's core DNA variant generation technology enables construction of comprehensive, high-quality libraries for identifying novel proteins with improved properties. Revolve is currently offering a service for custom DNA variant library construction with industry leading performance and delivery time. Additionally, the company is developing an ultra-throughput protein-screening platform that will accelerate the pace of novel high-value protein discovery.